• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Italian Pharmaceutical Market Experienced Poor Performance in 2007 Read More Inside the Italy Pharmaceuticals And Healthcare Report Q3 2008

Posted on: Wednesday, 1 October 2008, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/research/99f4a5/italy_pharmaceutic) has announced the addition of the "Italy Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.

The Italy Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Italy's pharmaceuticals and healthcare industry

The Italian pharmaceutical market experienced poor performance in 2007. Following sub-1% annual growth during 2005 and 2006, the market eventually shrunk in 2007, which was largely as a result of successive price cuts during 2006. Repeated market contraction is not expected in local currency terms. BMI expects drug expenditure to show minimal growth during 2008-2012 reaching EU24.6bn, which equates to a compound annual growth rate (CAGR) of 1.44%. Poor growth in local currency will be accentuated by a strengthening US/EUR exchange rate, leading to stagnation over the full forecast period in dollar terms.

Market expansion will be largely pushed forward by increased spending on OTC goods. Growth in the prescription sector will be characterised by increases in volume of prescriptions as well as the use of high price drugs such as oncology treatments, while increases in generic substitution and government scrimping will prevent the state drug bill from spiralling. BMI's new Burden of Disease Database ranks Italy as the 8th least healthy country in Western Europe. During 2008 5.9mn disability-adjusted life years (DALYs) will be lost with the majority accounted for by neuropsychiatric conditions and cardiovascular disease. This is similar to other Western European countries. While the disease burden will drop by 2030, we expect Italy to lose ground on its Western European neighbours, slipping to 10th position by 2030.

Company developments this quarter have seen Recordati build on its strong 2007 results after posting figures showing further growth in Q108. Meanwhile Newron Pharmaceuticals also acquired UK firm Hunter-Fleming after a long standing alliance between the two firms. Biotech firm Molmed has also begun trials for its leukaemia candidate which is being co-developed with Japanese firm Takara Bio.

Key Topics Covered:

Executive Summary

Table: Italy Pharmaceuticals And Healthcare Industry SW

Italy Political SWOT

Italy Economic SWOT

Pharmaceutical Business Environment Ratings

Table: Western Europe Pharmaceutical Business Environment Rankings

Limits Of Potential Returns

Risks To Realisation Of Returns

Market Summary

Healthcare Sector

Regulatory Regime

Intellectual Property Developments

Pricing And Reimbursement Issues

Industry Developments

Company Developments

Recordati Impresses In 2007

Biotechnology

Clinical Trials

Wholesale and Pharmacy Sectors

Epidemiology

Table: Disease Burden In Western Europe

Industry Forecast Scenario

Overall Market Forecast

Table: Drug Market Indicators

Key Growth Factors - Industry

Table: Health Expenditure Indicators

Key Growth Factors - Macroeconomic

Table: Italy - Macroeconomic Forecasts

Prescription Market Forecast

Table: Prescription Market Indicators

OTC Market Forecast

Table: OTC Market Indicators (US$mn unless otherwise stated

Generics Market Forecast

Table: Generics Market Indicators

External Trade Forecast

Table: Pharmaceutical Trade Indicators (US$mn)

Medical Devices

Table: Italy's Medical Device Market, 2006-2012 (US$bn unless otherwise stated

Other Healthcare Data Forecasts

Table: Italian Socio-Demographic Indicators

Competitive Landscape

Company Profiles

Leading Multinational Manufacturers

GlaxoSmithKline

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Indigenous Manufacturer

Recordati

BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

Companies Mentioned:

GlaxoSmithKline

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Indigenous Manufacturer

Recordati

For more information visit http://www.researchandmarkets.com/research/99f4a5/italy_pharmaceutic

Source: Business Wire

More News in this Category